Why Innate Pharma S.A.’s (IPHA) Stock Is Down 5.26%
As of Wednesday, July 08, Innate Pharma S.A.’s IPHA share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Commentary & Analysis
Why Innate Pharma S.A.’s (IPHA) Stock Is Up 6.67%
As of Monday, July 06, Innate Pharma S.A.’s IPHA share price has surged by 6.67%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Innate Pharma S.A.’s (IPHA) Stock Is Up 7.26%
As of Monday, June 29, Innate Pharma S.A.’s IPHA share price has surged by 7.26%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Innate Pharma S.A.’s (IPHA) Stock Is Up 5.03%
As of Friday, June 26, Innate Pharma S.A.’s IPHA share price has surged by 5.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Innate Pharma S.A.’s (IPHA) Stock Is Down 6.42%
As of Thursday, June 25, Innate Pharma S.A.’s IPHA share price has dipped by 6.42%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $194.0 | $282.5 | 27% |
|
| Shares Out (Mil) | 108.3 | 54.1 | 64% |
|
| Institutional Ownership | 66.8% | 92.9% | 41% |
|
| Float (Mil) | 70.7 | 41.5 | 55% |
|
| Beta | 0.88 | 0.94 | 52% |
|
| Avg Daily Volume (000s) | 28 | 469 | 23% |
|
| Price Change (52-week) |
1.4% | 59.1% | 49% |
|
| Growth | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (34.1%) | 14.1% | 1% |
|
| Net Income (5yr) | 5.9% | (10.1%) | 49% |
|
| EPS (5yr) | 8.2% | 15.9% | 43 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 12.5% | (15.6%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($58) | ($43) | 15% |
|
| EPS (TTM) | ($0.644) | ($1.500) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($44) | $2 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $4 | 31% |
|
| Enterprise Value (Q1) (Mil) | $160 | $195 | 24% |
|
| Valuation | IPHA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (384.4%) | 66.9% | 1% |
|
| Net Margin | (546.1%) | (74.2%) | 1% |
|
| ROA | (61.2%) | (47.6%) | 10% |
|
| ROE | 706.8% | (55.0%) | 100% |
|
| Liabilities to Assets | 134.6% | 29.6% | 97% |
|
| F-Score | 0 | 3 | 0% |
|
Innate Pharma S.A. did not pass any screens on 9/1/2026.
